To Evaluate the Efficacy and Safety of TQB3728 Tablets in Sequential Maintenance of TQB2450 Injection Therapy in Patients After Sequential or Concurrent Chemoradiation for Locally Advanced Non-small Cell Lung Cancer

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
It's a Phase Ib/II clinical trial to evaluate the efficacy and safety of TQB3728 tablets in sequential maintenance TQB2450 injection therapy in patients after sequential or concurrent chemoradiation for locally advanced non‐small cell lung cancer. Incidence and severity of adverse events (AEs), the type of dose‐limiting toxicity(ies) (DLT[s]) and Recommended phaseII dose(RP2D) were the Phase Ib primary endpoint. Overall response rate (ORR) was the Phase II primary endpoint.
Epistemonikos ID: 798b435b7778f2fd5e02bbc8aeb81b82a78bbe4d
First added on: Feb 19, 2024